| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/18/2002 | WO2001085798A3 Human monoclonal antibodies to dendritic cells |
| 07/18/2002 | WO2001085790A3 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 07/18/2002 | WO2001084565A3 Method and apparatus for manufacture of magnetizable microparticles |
| 07/18/2002 | WO2001083525A3 Modified peptides, comprising an fc domain, as therapeutic agents |
| 07/18/2002 | WO2001071359A3 Methods for identifying and isolating tissue-specific lumen-exposed molecules |
| 07/18/2002 | WO2001068142A9 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 07/18/2002 | WO2001056547A3 Preparation of aqueous clear solution dosage forms with bile acids |
| 07/18/2002 | WO2001045679A3 Use of chemotherapeutic agents for topical treatment |
| 07/18/2002 | WO2001032217A3 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 07/18/2002 | WO2001006991A9 Oil-in-water emulsion with improved stability |
| 07/18/2002 | US20020095108 Photoreduction method for hemoglobin-visicle |
| 07/18/2002 | US20020094971 Hyperglucemic, antidiabetic agents comprising a granulated starch having a reduced surface available for enzymatic degradation to delay production of reducing sugars; oral time-release agents; surgical patients; athletes |
| 07/18/2002 | US20020094970 Compositions and methods for treating an arthritic condition |
| 07/18/2002 | US20020094964 Use of somatostatin analogs for the delivery of anti-tumor drugs to tumor cells |
| 07/18/2002 | US20020094959 By injecting a biocompatible solution, with a given intrinsic viscosity, similar to a fatty acid mixture normally present in a healthy fat pad; treating heel pain |
| 07/18/2002 | US20020094950 Preselected enzyme cleavage points are stable in blood but are cleavable within cells; use in drug delivery such as of antitumor agents |
| 07/18/2002 | US20020094347 A neuro-active molecule, other than dopamine, within a microsphere comprising a biocomatible polymer having kinetic characteristics that may be manipulated to allow for the permeation of drug through polymer at controlled rate |
| 07/18/2002 | US20020094343 Topical dermal anaesthetic |
| 07/18/2002 | US20020094342 Contacting skin with skin treatment composition having concentration of 1-(3-methoxybenzyl)-3-substituted thiourea compound effective for inhibiting free radical generation |
| 07/18/2002 | US20020094338 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 07/18/2002 | US20020094334 Using variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between A and B chains; treatment of human immunodeficiency virus |
| 07/18/2002 | US20020094326 Treating tissue with phosphodiesterase inhibitor compound and administering exogenous nucleic acid |
| 07/18/2002 | DE10065217A1 Transfektionskomplexe (TransoPlex) mit reduzierter Toxizität, hoher physikalischer Stabilität und hoher Transfektionseffizienz sowie Verfahren zu ihrer Herstellung Transfection (TransoPlex) with reduced toxicity, high physical stability and high transfection efficiency and process for their preparation |
| 07/18/2002 | CA2776023A1 Fumaric acid amides |
| 07/18/2002 | CA2725833A1 Spaced drug delivery system |
| 07/18/2002 | CA2697520A1 Use of lyophilised reduced diaminophenothiazines in the treatment of tau mediated neurological disorders |
| 07/18/2002 | CA2434409A1 Amphiphilic derivatives for the production of vesicles, micelles and complexants, and precursors thereof |
| 07/18/2002 | CA2434402A1 Modular transfection systems |
| 07/18/2002 | CA2434077A1 Cyclodextrin preparations |
| 07/18/2002 | CA2433742A1 Proteins and nucleic acids encoding same |
| 07/18/2002 | CA2432350A1 Method for inhibiting the expression of a target gene |
| 07/18/2002 | CA2432319A1 Pulmonary delivery of polyene antifungal agents |
| 07/18/2002 | CA2431566A1 Topical testosterone formulations and associated methods |
| 07/18/2002 | CA2431543A1 Method of producing porous tablets with improved dissolution properties |
| 07/18/2002 | CA2431236A1 Therapeutic film forming composition and treatment system |
| 07/18/2002 | CA2428497A1 Targeted modification of intracellular compounds |
| 07/18/2002 | CA2428075A1 Fumaric acid derivatives as nf-kappab inhibitors |
| 07/18/2002 | CA2427146A1 Transcobalamin binding conjugates useful for treating abnormal cellular proliferation |
| 07/17/2002 | EP1222932A1 Compositions for electroporation |
| 07/17/2002 | EP1222931A1 Percutaneous absorption promoters for electroporation |
| 07/17/2002 | EP1222926A1 Cationic polysaccharide compositions |
| 07/17/2002 | EP1222923A1 Nicotine transdermal delivery composition for smoking cessation |
| 07/17/2002 | EP1222922A1 Method for stabilizing benzimidazole compounds |
| 07/17/2002 | EP1222918A1 Microcapsules for stabilizing cosmetic, pharmaceutical or food products |
| 07/17/2002 | EP1222289A2 Chimeric immunogenic compositions and nucleic acids encoding them |
| 07/17/2002 | EP1222275A2 Serum amyloid a isoform from colostrum |
| 07/17/2002 | EP1222217A1 Uniform molecular weight polymers |
| 07/17/2002 | EP1222171A1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 07/17/2002 | EP1222018A1 Use of galactomannans as an emulsifying agent |
| 07/17/2002 | EP1221985A1 Conveyance of anti-infective activity to wound dressings |
| 07/17/2002 | EP1221975A2 Polymer stabilized neuropeptides |
| 07/17/2002 | EP1221974A2 Magnetic targeted carrier |
| 07/17/2002 | EP1221971A2 Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 07/17/2002 | EP1221965A1 Use of tgf beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| 07/17/2002 | EP1221964A2 Antigenic modification of polypeptides |
| 07/17/2002 | EP1221957A2 Method for preparing a composition by mother-of-pearl extraction,and use thereof in cosmetics and dermatology |
| 07/17/2002 | EP1221949A2 Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses |
| 07/17/2002 | EP1221947A2 Soft gel capsule resistant to gastric juices |
| 07/17/2002 | EP1221943A2 Method of producing sub-micron particles of biologically active agents |
| 07/17/2002 | EP1221942A1 Biodegradable microparticles with novel erythropoietin stimulating protein |
| 07/17/2002 | EP1221941A1 Powder pharmaceutical formulations |
| 07/17/2002 | EP1221940A2 Liposome formulation of 6,9-bis- (2-aminoethyl)-amino]benzo g]isoquinoline-5,10-dione dimaleate |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP1221938A2 Method for producing liposome preparation |
| 07/17/2002 | EP1221937A2 Hybrid matrices and hybrid matrix mixtures |
| 07/17/2002 | EP1221926A1 Pharmaceutical formulations containing poorly soluble drug substances |
| 07/17/2002 | EP1221917A1 Drug delivery device |
| 07/17/2002 | EP1221908A1 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/17/2002 | EP1221863A1 Chewing gum containing medicament active agents |
| 07/17/2002 | EP1221841A1 Encapsulated active material immobilized in hydrogel microbeads |
| 07/17/2002 | EP1221840A1 Active material within hydrogel microbeads |
| 07/17/2002 | EP1123104A4 Inherently antimicrobial quaternary amine hydrogel wound dressings |
| 07/17/2002 | EP1100474B1 Two-piece capsule for receiving pharmaceutical preparations for powder inhalers |
| 07/17/2002 | EP1066056B1 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition |
| 07/17/2002 | EP0969860B1 Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
| 07/17/2002 | EP0934082B1 Process for producing biologically active polymer nanoparticle-nucleic acid conjugates |
| 07/17/2002 | EP0866709A4 1,2,4-benzotriazine oxides formulations |
| 07/17/2002 | EP0842662B1 Percutaneous tape preparation containing fentanyl |
| 07/17/2002 | EP0755246B1 Ophthalmic composition containing an ion sensitive, hydrophilic polymer and an inorganic salt in a ratio which gives low viscosity |
| 07/17/2002 | EP0735862B1 Method for dry blend compression of medicaments |
| 07/17/2002 | CN1359469A Epitopes formed by non-covalent association of conjugates |
| 07/17/2002 | CN1359420A Novel indications of mannan-binding lectin (MBL) in the treatment of immunocompromised individuals |
| 07/17/2002 | CN1359392A Coupled compound of erythropoietin with glycol |
| 07/17/2002 | CN1359381A Thiazole-derivaties |
| 07/17/2002 | CN1359370A Esters of L-carnitine or alkanoyl L-carnitines |
| 07/17/2002 | CN1359303A Pharmaceutical complex |
| 07/17/2002 | CN1359299A Keratinocyte growth factor-2-formulations |
| 07/17/2002 | CN1359298A Novel indications of mannan-bindie lectin (MBL) in the treatment of immanocompromised individuals |
| 07/17/2002 | CN1359294A Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel |
| 07/17/2002 | CN1359288A Method for improvement of transport across adaptable semi-permeable barriers |
| 07/17/2002 | CN1359262A Therapeutic anti-fungal nail preparation |
| 07/17/2002 | CN1358703A Powder shape mannitol and process for preparing same |
| 07/17/2002 | CN1358542A Jusheng oil and preparation process |
| 07/17/2002 | CN1358499A Animal phisiologicla and biological activity regulation agent composition containing cysteamine and its salt |
| 07/17/2002 | CN1358495A Film forming spraying agent |
| 07/17/2002 | CN1358494A Composition for increasing osmosis of local skin reagent |
| 07/17/2002 | CN1087779C Macroencapsulated secretory cells |
| 07/17/2002 | CN1087609C Chalcones and esters thereof with antiproliferative activity ini uterus, ovary and breast tumours |
| 07/16/2002 | US6420551 Antisense oligonucleotides targeted against human immunodeficiency virus |
| 07/16/2002 | US6420542 Tie ligands |